Join in the fight against Covid/Flu Viruses
Are you eligible for our vaccine clinical research studies?
• No health insurance required
• Compensation for time and travel for qualified patients

Call Today!

IMA Clinical Research is seeking healthy adults for our
groundbreaking vaccine research studies.
We are hoping to find new and effective options to fight
against the Covid and Influenza viruses.


• Ages 18 – 64
• In Generally Good Health

Benefits of Participation

• Potentially discover new and effective treatment options
• Compensation provided for time and travel (for qualified
• No health insurance required
Together we can make a real difference in medical advancements. Join us on our journey toward improved immunity!
To learn more about our studies and how to participate:
Call us

The Future of Flu Starts With You

You have the power to advance research that may change the future of seasonal influenza (flu) with 1 injection. Learn more about participating in the Ignite P303 Trial for an investigational vaccine aimed at preventing seasonal flu infection.

Seasonal flu vaccines during the 2021-2022 flu season were2:







A messenger RNA (mRNA) vaccine may offer broader protection by responding to changes in seasonal flu strains more quickly and creating stronger immune responses3.
The Ignite P303 Trial will look at the safety and immune response of an mRNA-based investigational vaccine aimed at preventing seasonal flu in adults aged 18 and older.

Who Can Join?
This clinical trial is looking for adult participants. To join, you must be:
⚪ 18 years of age or older
⚪ In good health
⚪ Not pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit
Prior to enrolling in this trial, you should:
⚪ Not have received a seasonal flu vaccine in the past 5 months
⚪ Not have had a confirmed flu infection within 5 months


1. Influenza (seasonal): ask the expert: influenza Q&A. World Health Organization. Published November 6, 2018.
2. Price AM, Flannery B, Talbot HK, et al. Influenza vaccine effectiveness against influenza A(H3N2)-related illness in the United States during the 2021-2022influenza season. Clin Infect Dis. 2022;ciac941. doi:10.1093/cid/ciac941
3. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8(11):1745.

Download Poster

    • VA: Greetings, I am Indago's Virtual Assistant. Kindly note that the information I provide may not be guaranteed for accuracy and my voice is AI generated. How may I help you? También hablo español y otros idiomas

    Virtual Assistant is thinking... ...
  • Virtual Assistant
    Skip to content NULL